
|Articles|February 25, 2022
Unique Solutions to Semi-Solid Dosage Form ANDA Project
Author(s)LGM Pharma
When the patent on a brand-name dental paste expired, our client saw an opportunity to offer sufferers of painful oral lesions a generic alternative. Their product would drive down costs for patients while positioning the client’s business for success in a competitive market. With the FDA’s Abbreviated New Drug Application (ANDA) regulatory pathway leading the way forward, all they needed was a partner with experience developing and manufacturing unique semi-solid products. That’s when they found LGM Pharma. Read our case study.
Trending on Pharmaceutical Technology
1
What FDA's AI Warning Letter Tells Us About GMP Accountability
2
Why Are Drugmakers Racing to Acquire ADC Payload Platforms?
3
The Role of Standards in the Drug Supply Chain
4
Daraxonrasib Review Signals Shift in EU Drug Assessment Rules
5